Archive: 09/04/2013

Clinical trial results for BIND-014 presented at AACR 2013

The nanoparticle drug BIND-014 is effective against multiple solid tumors, according to results generated by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, and presented today at the American ...

Quantifying heterogeneity in breast cancer

A variety of mutations may give rise to breast cancer, but scientists generally assume that it starts off with just a few. That's because later-stage breast cancers tend to have more mutations—they are more heterogeneous—than ...

New technology spots drugs' early impact on cancer

A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, ...

page 4 from 11